Natera (NASDAQ:NTRA) Stock: Insider Solomon Moshkevich Sells 3,000 Shares

Key Points

• Insider sale: Solomon Moshkevich sold 3,000 Natera shares for approximately $1.24 million under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 2.73% to 106,914 shares.
• Strong stock performance: Natera shares traded at $410.35, near their 52-week high of $427.47, with the stock up substantially above its 50-day and 200-day moving averages.
• Growth and analyst outlook: Natera’s latest quarterly revenue rose 37.7% year over year and exceeded expectations, while analysts maintained a “Moderate Buy” consensus rating with an average price target of $341.55.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00. Following the completion of the transaction, the insider directly owned 106,914 shares in the company, valued at $44,285,917.08. This trade represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90.

Natera Trading Up 0.5%

Shares of NTRA stock traded up $1.88 during mid-day trading on Friday, reaching $410.35. The stock had a trading volume of 2,156,324 shares, compared to its average volume of 1,566,597. The stock's 50-day moving average price is $332.39 and its two-hundred day moving average price is $261.01. Natera, Inc. has a 52-week low of $160.59 and a 52-week high of $427.47. The firm has a market capitalization of $59.15 billion, a PE ratio of -301.73 and a beta of 1.50.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.Natera's quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the firm earned ($0.74) earnings per share. On average, equities research analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of research analyst reports. The Goldman Sachs Group assumed coverage on shares of Natera in a research report on Friday, June 5th. They set a "neutral" rating and a $245.00 price objective on the stock. Citigroup lifted their target price on shares of Natera from $315.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 13th. Canaccord Genuity Group set a $375.00 price target on shares of Natera in a research report on Friday, August 7th. Wells Fargo & Company increased their price target on shares of Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Finally, UBS Group raised their price objective on shares of Natera from $290.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $341.55.

Hedge Funds Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. BlackRock Inc. bought a new position in Natera during the 2nd quarter valued at about $2,962,770,000. JPMorgan Chase & Co. grew its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Bank of America Corp DE purchased a new position in shares of Natera during the second quarter valued at approximately $199,960,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Natera by 111.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,179,939 shares of the medical research company's stock valued at $270,312,000 after purchasing an additional 620,954 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in Natera during the second quarter valued at approximately $150,143,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.